According to the journal ‘Science’, in October 2020, “The World Health Organisation’s Solidarity Trial showed that remdesivir does not reduce mortality or the time covid-19 patients take to recover.” And “a second, smaller placebo-controlled study of remdesivir on hospitalised covid-19 patients in China, published online by The Lancet on 29th April 2020, found no statistically significant benefit from the treatment – and the antiviral surprisingly had no impact on levels of the coronavirus.” I find it difficult to see why the FDA, the EU and the UK’s drug regulator all approved remdesivir, though they appear to have done so without worrying too much about the research showing that it was pretty useless.
Side effects which can occur in patients taking remdesivir may include: • Puffiness or swelling of the eyelids or around the eyes, face, lips or tongue • Yellow eyes or skin (a possible sign of liver problems) You will be relieved to know that not all patients would be expected to have all of these side effects, though a number of these side effects are classified as “common.” Please share this article with everyone you know.
Any doctor prescribing remdesivir should know of these interactions – which are listed on the NICE website.
Remdesivir was introduced for the treatment of covid-19 patients who were in hospital suffering from covid-19, with or without pneumonia.
If you are being given Veklury, you are being given remdesivir.
Remdesivir is described as a “broad spectrum antiviral drug.” It is an RNA polymerase inhibitor which disrupts the production of vital RNA.
You can form your own opinion on whether remdesivir ever has a value by reading the following information.
https://expose-news.com/2024/08/30/remdesivir-what-you-must-know/
No comments:
Post a Comment